Larimar Therapeutics Inc
NASDAQ:LRMR 3:59:54 PM EDT
Earnings Announcements
Larimar Therapeutics Reports First Quarter 2022 Operating And Financial Results
Published: 05/12/2022 11:10 GMT
Larimar Therapeutics Inc (LRMR) - Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results.
Q1 Loss per Share $0.49.
Cash at March 31, 2022 of $62.6 Million Provides Projected Cash Runway Into Q3 of 2023.
Q1 Loss per Share $0.49.
Cash at March 31, 2022 of $62.6 Million Provides Projected Cash Runway Into Q3 of 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.57
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.54
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.57
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.54
More details on our Analysts Page.